[ad_1]
By Ludwig Burger
FRANKFURT (Reuters) – Bayer
gi
Managing Director, Werner Baumann, is under pressure to increase Bayer's share price after falling more than 35% since the beginning of the year, driven by concern over more of 9,000 lawsuits for cancer that would have caused Monsanto's Roundup cancer.
The group is studying strategic options for the Coppertone product lines for sunscreens and Dr. Scholl's for foot care, among the leading brands of Merck & Co
Bayer will also divest its animal health division, the industry 's number five, which badysts say could bring in 6 to 7 billion euros.
It would seek a buyer for its 60% stake in the German supplier of chemical production site services, Currenta.
The three possible transactions were previously reported by Reuters reports.
As part of a cost reduction program that will also address the synergies expected from the $ 63 billion acquisition of Monsanto, Bayer will eliminate approximately 12,000 of its 118,200 jobs worldwide.
In the Consumer Health and Pharmaceuticals Divisions, Bayer will absorb approximately 3.3 billion euros in write-downs and write-offs in the fourth quarter.
The Consumer Health brands acquired with Merck & Co. and Dihon will account for 2.7 billion euros, while write – offs and write – offs of around 600 million euros are due to the decision of do not use a hemophilia manufacturing facility in Wuppertal, Germany. and concentrate production in Berkeley, United States.
(Report by Ludwig Burger, edited by Tbadilo Hummel)
Source link
